ERBB2 and breast cancer: Yan et al. [12] developed a prediction model in a primary cohort consisting of 498 patients with invasive breast cancer, and the data were gathered from July 2016 to September 2018 to predict pathological complete response and tumor shrinkage size in breast cancer considering an ML approach, i.e., LR, on Breast Cancer Cinoma (BCC) using the Harbin Medical University Cancer Hospital (HMUCH) dataset and resulted in a nomogram for HER2-positive and triple-negative breast cancer (TNBC) with an AUC of 0.820 and 0.785, respectively.